Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I made no such claim. But it's funny it takes a tweet to figure out if he's still a shareholder or not. Management never mentions him. No current filings. What about the others?
It's not. We went through all this a year ago or whenever it was. But that article does say he had other personalized vaccines too.
>>He continued to receive immunotherapy and other personalised vaccines for his tumour.
Remember this doc? Long way to go but he's in good shape so far.
>>The team of doctors has started preparing the paperwork for the trials and the positive results of the trial are expected to shake up the current treatment of cancer which has remained unchanged for 19 years for millions of patients.
https://www.independent.co.uk/news/world/australasia/glioblastoma-cancer-treatment-richard-scolyer-b2544548.html
https://www.bbc.com/news/world-australia-69006713
Wow, you set a really high bar! lol. Maybe you haven't noticed but Les is the face of NWBO since the CEO CFO Chair hasn't done a presentation in five plus years.
BioHarm doesn't think retail folks here need to know about such things as old contracts, whether with employee, UCLA or other.
When and if LP ever does emerge from where ever she is, I expect her to tell retail shareholders something like "Do you want the good news or the bad news first?"
Nemesis said the "Alternative DCVAX". UCLA clearly owns their original version. But, as LL pointed out, it's nearly impossible to successfully patent a patients own cells so companies like NWBO patent their own process. Private Advent now has all the man power and knowhow to move the process along. Then there's Flaskworks, LLC.
That's why I think these posters must be paid in some way. Because nobody could be that stupid as to shrug away the history and LP's private set ups.
I wish AF knew about Les' most recent appearance on the BigBiz Show. He'd have a field day, I suspect.
Likely. UCLA & James River too.
UCLA is a lot more than just a "Teaching institution", you dolt. UCLA Health is massive.
>>A study by the Rand Corporation about leadership structures at UCLA Health again addresses the ambiguous position of UCLA Health as both an academic and a commercial entity.[3] More recently,[when?] the UCOP has scheduled a bylaw amendment for the Committee on Health Services with a view to changing the composition of the leadership structure to enable the UCLA Health System (then so-called) to compete and collaborate more effectively in the health services marketplace.
I think it depends on what UCLA wants. I know they've been building out their own manufacturing capacity. The real question is Does UCLA want to be a "Lab to patient treatment center" or farm it out to BP or NWBO or both? The trend seems to be keeping it in house?? It could be the partner negotiations LP claims to be currently working on?? That UCLA agreement with NWBO is very old from what I can tell. Maybe even expired much like their employee agreements. LOL.
I don't think NWBO could claim to be an "Instrumental component" of the actual DCVAX-L research that UCLA owns, but could be wrong. NWBO does own the Plll data so it might make sense to play ball, although I suspect UCLA has that too. LP did just sign LL on as an SA so that seems positive.
It's never been clear the two DC products are very different. Possibly administered differently or frozen-fresh, as Ex points out. Possible cell maturity differences??
I suspect it's Flaskworks (Process) that differentiates NWBO's L more than anything. It's why all the stalling, IMO.
But the biggest question, IMO, is always Who really benefits from all this the most, private Advent or public NWBO?
No. NWBO does the process.
>>UCLA didn't develop DCVax-L by themselves, it was collaborative with NWBO as I understand it.
So what does LP do, she sells off private U.S. Cognate and builds private UK Advent public Sawston facility.
>>So, with a DC vaccine, like I said, we can just make it ourselves. We can’t scale up as an academic institution or a small company, but if that were part of the company we could scale up. To make the vaccine, you just need a manufacturing GMP facility. But the problem there is the autologous dendritic cells are hard to get patented. You could patent it, but it’s hard to defend that because it’s really the patient’s own tumor, right?
So, the patents really are process patents and we could file one that tweaks things a little bit, and that’s essentially that’s what Northwest Bio did. They filed multiple patents just on little tweaks of the cocktails that are used to make the cells.
>>For instance, consider the trial that I’ve done for dendritic cell vaccines. For cellular therapies, I think what is lacking is a smooth, operational aspect. Let’s say, if there was a company that could make GMP-grade cells readily and basically, it’s almost like the manufacturing, production, distribution, and coordination of the treatment or clinical trial for approval for a treatment would go much more smoothly.
I think that’s what’s lacking. And the ideal company would be like, almost like an Uber or Amazon. Basically something that turns and existing industry upside down. I think we need something that turns the—not only the clinical trial to FDA approval process upside down, but also how to scale that up once something is approved or adopted.
https://billmalloy.info/qa-with-linda-liau/
Welcome. Here's that link I forgot to post.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514134/
Found this. It coming back to me now.
>>DCVax®-L phase I and II clinical trials
Data on these trials derive mainly from NWBT public reports. Prior to the ongoing phase III trial two phase I/II trials were carried out at the University of California, Los Angeles (UCLA) by Dr. Linda Liau and Dr. Robert Prins on this product.
You can thank him but it's not entirely accurate. Cognate (Sold off by LP) made the L for the Plll trial while UCLA produced the Pl and other follow up "study trials", but never really anything identified as "Pll", that I can recall.
Here's where it all pretty much started.
https://aacrjournals.org/clincancerres/article/11/15/5515/185993/Dendritic-Cell-Vaccination-in-Glioblastoma
It's murky along with my memory. I want to say that UCLA did the tiny Pll with NWBO having done an IP deal at some point.
>>We conducted this study at over 80 sites in 4 countries: the US, Canada, Germany, and the UK. Patient recruitment was initiated in 2007, and was paused from 2009 to 2011 for economic reasons. The midpoint of enrollment was reached in May of 2014, and the final patient was enrolled in November of 2015.
The Plll was first posted in 2002 and morphed from the Pll so a whole lot longer than that.
>>We conducted this study at over 80 sites in 4 countries: the US, Canada, Germany, and the UK. Patient recruitment was initiated in 2007, and was paused from 2009 to 2011 for economic reasons. The midpoint of enrollment was reached in May of 2014, and the final patient was enrolled in November of 2015.
Why don't you tell George who did?
The company told a select TV audience that they think L is going to be SOC not just another competing therapy. No filing. No PR.
CEO didn't say it. Not even a filing or PR to cover themselves.
"future of the standard of care, which is what it’s going to be we believe"
>>Anyone who wants to use DC for the future of the standard of care, which is what it’s going to be we believe, will have to come through our patents, because they’re very broad. And, we think this will be the future.
They don't need Eden just for GMB. It'll take years for market penetration, coordination with hospitals and surgeons to find any cost savings, assuming L somehow gets the MHRA-NICE nod for full approval and full coverage. But I guess LP can tell NICE they can do it for a discount at $X while NWBO never sees any real revenues. But Advent likely will.
You cannot make this stuff up!
"Comma placement"
Note: No transcript -no filing of event even when everything is allegedly "so close" and on the line.
Ignore these Borg because you know, no matter what they say, they cling onto your every word. That's because somewhere in their misfiring neural network there's still a connection to common sense, and you provide a path. There still may be hope!
The BBS gives Les just enough time so he can entice viewers but never explain anything thoroughly enough to make sense of it.
That's from kids across America jumping around channels and landing in the BBS.
Reckless BBS, not even a mention of governance, shares outstanding, financial condition. It's just sick.
That's not how it works. If a deal were really in works, Les would be ordered by the suitor to shut it. LP and LG's strategy is go after the Reddit crowd, IMO. Keep investors all powerless retail with no Kingfish who could ever disrupt the Advent relationship.
Oh you can forget about all that now...Right out the window! His eye appears to be on Reddit as a solution for the summer.
>>He went to the show to entice new retail to invest in NWBO. Which also indicates there will be no buyout or significant non dilutive cash injection in the form of partnership(s) or franchise(s) in the near term.
And, for some reason he felt compelled to tell the "Evil shorts" he had 50,000 investors without mentioning any lead or institution to support the sp, and while simultaneously saying this summer's going to be slow.
And the hermit CEO CFO doesn't even do it herself, instead she sends out 80 something-frail looking-General Council, Les, who has "TV experience".
I find it completely unbelievable that a biotech allegedly waiting for regulatory approval on another continent for a living cell-state of the art -cancer vaccine, would release such regulatory timing information to a home TV audience. The company didn't even send out an email or PR to their shareholders or informed hardcore investors!
>>Senior Vice President, General Counsel
lgoldmanMr. Les Goldman joined us as Senior Vice President, Business Development in June 2011. Prior to joining us, Mr. Goldman was a partner at the law firm of Skadden, Arps for over 30 years, specializing in a wide array of advanced technologies and their commercialization. Mr. Goldman also serves as an advisor to a number of other technology companies. In addition, for eight years, Mr. Goldman served as Chairman of the Board of a group of TV stations in four mid-size cities across the country.
Like I said the other day; they'll drag it out as long as possible so think September.
Eye rolls. Nothing set yet and they can basically call it in.
Imagine making an appearance to tell Wall Street that he has 50,000 retail shareholders and nothing is happening until after the summer. Lots of chop licking.
I think that was Les' way of saying Don't bother me with all the calls until after the summer is over. LOL.
Note also nothing in there about material information and reporting properly. Just "No news is good news" see you in the Fall. Eye rolls.
Looks like everyone is going to have a nice relaxing summer. Funny how the timing works. I'm thinking of taking off from here until September too.
Ugh...Another entry level disciple.
>>think about it, who would sit on a message board for a stock they hate
At least he blurred out his bedroom den in the background this time.
It's how he provides social media warriors with back and forth dialog.
>>He says on track for accelerated decision (150 days) which is new info.
He proceeds to say they hope to have something to share on MAA in “late fall”. Which is nowhere near “accelerated”. What a horrible way to update your timeline.
50,000 retail...Congrats to DanishDancer!
Guys...come on...really, are you ever going to figure this out? I'm getting old.